ATC code: N05AF05
Zuclopenthixol is an antipsychotic agent of the first generation that blocks dopamine D2-receptors. Sex differences regarding the antipsychotic effect or adverse events have not been reported.
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of zuclopenthixol have been found.
No studies with a clinically relevant sex analysis regarding the antipsychotic effect of zuclopenthixol have been found.
Publications reporting sex differences of zuclopenthixol regarding adverse effects were not found. However, a register based study in patients older than 65 years (179 men, 356 women) did not detect any sex difference regarding the risk of death with zuclopenthixol [1].
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Updated: 2019-09-07
Date of litterature search: 2019-07-20
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson